Amount of accrued additional upfront license fee.

No definition available.

Name:	lqda_AccruedAdditionalUpfrontLicenseFee
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of contingent milestones and royalties accrued as of the end of the reporting period.

+ References

No definition available.

+ Details

Name:	lqda_AccruedContingentMilestonesAndRoyalties
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Expiration term of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	lqda_AgreementExpirationTerm
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Term term upon written notice in the event of application for regulatory approval is not received by FDA within the specified period.

+ References

No definition available.

+ Details

Name:	lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Term term upon written notice in the event of application for regulatory approval is rejected by the FDA.

+ References

No definition available.

+ Details

Name:	lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Initial term of submission of quarterly forecast of expected production considered as binding firm order.

+ References

No definition available.

+ Details

Name:	lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The maximum future contingent milestones and royalties on net sales.

+ References

No definition available.

+ Details

Name:	lqda_MaximumFutureContingentMilestonesAndRoyalties
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The maximum potential development milestone payments per the agreement.

+ References

No definition available.

+ Details

Name:	lqda_MaximumPotentialDevelopmentMilestonePayments
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The maximum potential sales milestones to be paid.

+ References

No definition available.

+ Details

Name:	lqda_MaximumPotentialSalesMilestones
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of milestone payment for each additional indication approved by the FDA after PAH and PH-ILD and each additional product approved by the FDA under the license.

+ References

No definition available.

+ Details

Name:	lqda_MilestonePaymentForEachAdditionalIndicationOne
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of milestone payment for each additional indication approved by the PMDA after PAH and PH-ILD.

+ References

No definition available.

+ Details

Name:	lqda_MilestonePaymentForEachAdditionalIndicationThree
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of milestone payment for each additional indication approved by the EMA after PAH and PH-ILD.

+ References

No definition available.

+ Details

Name:	lqda_MilestonePaymentForEachAdditionalIndicationTwo
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of non-cancelable future commitments for product manufacturing and supply costs.

+ References

No definition available.

+ Details

Name:	lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of cash outflow for upfront license fee.

+ References

No definition available.

+ Details

Name:	lqda_PaymentForUpfrontLicenseFee
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of reimbursement of documented out of pocket expenditures for any capital equipment.

+ References

No definition available.

+ Details

Name:	lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures
Namespace Prefix:	lqda_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate amount of reimbursement capital expenditure incurred by the supplier after the effective date of agreement to perform the services for the company.

+ References

No definition available.

+ Details

Name:	lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Term of submission of quarterly forecast of expected production.

+ References

No definition available.

+ Details

Name:	lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_PharmosaLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=lqda_OtherThenNorthAmericaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_ChasmTechnologiesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_AgreementWithLGMPharmaLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) - USD ($) $ in Thousands			1 Months Ended	3 Months Ended
	Oct. 02, 2024	Jul. 14, 2023	Jun. 30, 2023	Mar. 31, 2025	Oct. 31, 2024
Non-cancelable commitments for product manufacturing and supply costs				$ 20,400
Pharmosa License Agreement
Upfront license fee to be paid			$ 10,000
Accrued additional upfront license fee					$ 3,500
Maximum potential development milestone payments	$ 37,750
Milestone payment for each additional indication approved by the FDA after PAH and PH-ILD and each additional product approved by the FDA under the license	10,000
Milestone payment for each additional indication approved by the EMA after PAH and PH-ILD	2,000
Milestone payment for each additional indication approved by the PMDA after PAH and PH-ILD	500
Pharmosa License Agreement \| North America
Maximum potential sales milestones	185,000
Pharmosa License Agreement \| Other then North America
Maximum potential sales milestones	$ 150,000
Chasm Technologies
Maximum future contingent milestones and royalties				1,500
Accrued contingent milestones and royalties				200
Agreement With LGM Pharma, LLC
Purchase Commitment, Remaining Minimum Amount Committed				$ 2,700
Expiration term of agreement				5 years
Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC
Termination term for FDA rejection		60 days
Termination term for FDA delay		120 days
Percentage of reimburse		50.00%
Aggregate exceed		$ 2,500
Term of submission		24 months
Initial term		12 months